Adverse event reports following Japanese encephalitis vaccination in the United States, 1999-2009

被引:20
|
作者
Lindsey, Nicole P. [1 ]
Staples, J. Erin [1 ]
Jones, James F. [2 ]
Sejvar, James J. [1 ]
Griggs, Anne [1 ]
Iskander, John [3 ]
Miller, Elaine R. [4 ]
Fischer, Marc [1 ]
机构
[1] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO 80521 USA
[2] CDC, Chron Viral Dis Branch, Atlanta, GA 30333 USA
[3] CDC, Off Associate Director Sci, Atlanta, GA 30333 USA
[4] CDC, Immunizat Safety Off, Atlanta, GA 30333 USA
关键词
Japanese encephalitis; Vaccine; Adverse event; VAERS; ACUTE DISSEMINATED ENCEPHALOMYELITIS; ALLERGIC REACTIONS; CASE-DEFINITION; SYSTEM VAERS; SAFETY; IMMUNIZATION; GUIDELINES; COLLECTION; SURVEILLANCE;
D O I
10.1016/j.vaccine.2010.10.016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We reviewed adverse events following receipt of inactivated mouse brain-derived Japanese encephalitis (JE) vaccine reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 1999 to 2009. During this period, VAERS received 300 adverse event reports following JE vaccination (24 per 100,000 doses distributed); 106 (35%) were classified as hypersensitivity reactions (8.4 per 100,000 doses) and four (1%) were classified as neurologic events (0.3 per 100,000 doses). Twenty-three (8%) reports described serious adverse events (1.8 per 100,000 doses distributed). There were no reports of encephalitis, meningitis, or Guillain-Barre syndrome. As reported previously, hypersensitivity reactions were common among persons receiving inactivated mouse brain-derived JE vaccine. Published by Elsevier Ltd.
引用
收藏
页码:58 / 64
页数:7
相关论文
共 50 条
  • [22] Post-Marketing Surveillance of Adverse Events Following Vaccination with the Live-Attenuated Japanese Encephalitis Chimeric Virus Vaccine (Imojev(R)) in South Korea, 2015-2019
    Kim, Hee Soo
    Oh, Yongho
    Korejwo, Joanna
    Castells, Valerie Bosch
    Yang, Kuhyun
    INFECTIOUS DISEASES AND THERAPY, 2020, 9 (03) : 589 - 598
  • [23] Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000-2013
    Hibbs, Beth F.
    Moro, Pedro L.
    Lewis, Paige
    Miller, Elaine R.
    Shimabukuro, Tom T.
    VACCINE, 2015, 33 (28) : 3171 - 3178
  • [24] Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children Analysis of the Vaccine Adverse Event Reporting System
    Muhammad, Riyadh D.
    Haber, Penina
    Broder, Karen R.
    Leroy, Zanie
    Ball, Robert
    Braun, M. Miles
    Davis, Robert L.
    McMahon, Ann W.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2011, 30 (01) : E1 - E8
  • [25] Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States
    Ojha, Rohit P.
    Jackson, Bradford E.
    Tota, Joseph E.
    Offutt-Powell, Tabatha N.
    Singh, Karan P.
    Bae, Sejong
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (01) : 232 - 237
  • [26] Hearing disorder following COVID-19 vaccination: A pharmacovigilance analysis using the Vaccine Adverse Event Reporting System
    Chen, Congqin
    Fu, Fang
    Ding, Lingqing
    Xiao, Jie
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (11) : 1789 - 1795
  • [27] Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013
    Subelj, M.
    Ucakar, V.
    Kraigher, A.
    Klavs, I.
    EUROSURVEILLANCE, 2016, 21 (14) : 8 - 13
  • [28] Characteristics and Comparison of Adverse Events of Coronavirus Disease 2019 Vaccines Reported to the United States Vaccine Adverse Event Reporting System Between 14 December 2020 and 8 October 2021
    Zou, Chenyu
    Xue, Xiangzhong
    Qian, Jingjing
    FRONTIERS IN MEDICINE, 2022, 9
  • [29] Spontaneous reports of primary ovarian insufficiency after vaccination: A review of the vaccine adverse event reporting system (VAERS)
    Wodi, Patricia
    Marquez, Paige
    Mba-Jonas, Adamma
    Barash, Faith
    Nguon, Kosal
    Moro, Pedro L.
    VACCINE, 2023, 41 (09) : 1616 - 1622
  • [30] Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO®, IC51
    Dubischar-Kastner, Katrin
    Eder, Susanne
    Buerger, Vera
    Gartner-Woelfl, Gabriele
    Kaltenboeck, Astrid
    Schuller, Elisabeth
    Tauber, Erich
    Klade, Christoph
    VACCINE, 2010, 28 (32) : 5197 - 5202